Memantina Aristo

Memantine, the active ingredient in Memantina Aristo, is a NMDA receptor antagonist presented as an oral tablet for oral use. It treats Alzheimer’s disease in adults by helping to preserve cognition and daily functioning.

GNH USA supplies Memantina Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Aristo is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

Alzheimer’s disease (moderate to severe): helps maintain cognition and daily functioning in patients with moderate to severe disease. Mild‑to‑moderate Alzheimer’s disease: may provide modest cognitive benefit in earlier stages. Behavioral symptoms of dementia: may reduce agitation and improve overall patient behavior.

Memantina Aristo may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, angioedema) - Hepatic dysfunction - Stevens‑Johnson syndrome - Suicidal thoughts or behavior

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: assess renal function and adjust dose if needed. - History of seizures: monitor closely for seizure activity. - Cardiovascular disease: monitor blood pressure regularly. - Concurrent use with other NMDA antagonists: avoid combined therapy. - Pregnancy: use only if potential benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from moisture.

Memantina Aristo can interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can exacerbate CNS effects. - Strong renal toxicants (e.g., high‑dose NSAIDs): may worsen renal clearance.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors: monitor for additive cognitive effects. - Diuretics: watch renal function and electrolytes. - Antihypertensives: observe for blood‑pressure changes.